Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Access SEC filings for Agenus Inc (NASDAQ: AGEN), providing regulatory documentation essential for understanding this clinical-stage immunology company's financial position, operational developments, and material events. These filings offer official disclosure of information required by securities regulations.
As a publicly traded biotechnology company, Agenus files regular reports with the Securities and Exchange Commission including quarterly reports (10-Q), annual reports (10-K), and current reports (8-K) for material events. These documents provide detailed information about the company's clinical programs, financial condition, risk factors, and corporate governance.
Key filing types relevant to Agenus investors include 8-K filings announcing clinical trial results, partnership agreements, and significant corporate developments. The company's 10-K annual reports offer comprehensive overviews of pipeline programs, competitive landscape analysis, and detailed financial statements with auditor opinions.
Proxy statements (DEF 14A) disclose executive compensation, board composition, and shareholder voting matters. Registration statements accompany securities offerings, providing prospectus information for capital raises that fund ongoing research and development activities.
Monitoring Agenus SEC filings enables investors to access official company disclosures before or concurrent with public announcements, supporting informed investment decisions. This page provides organized access to AGEN's complete filing history with the SEC.
Agenus (Nasdaq: AGEN) filed an 8-K detailing the results of its 17 June 2025 Annual Meeting, where 16.71 million shares—61.5 % of shares outstanding—were represented.
Board elections: Class I directors Brian Corvese (5.99 m for / 4.83 m withheld) and Timothy Wright (6.86 m for / 3.96 m withheld) were elected to serve until 2028.
Equity & compensation matters:
- Stockholders approved expanding the 2019 Equity Incentive Plan to 12.05 m shares, adding 7.0 m shares (6.14 m for / 4.59 m against / 0.08 m abstain).
- They approved raising share limits on the Directors’ Deferred Compensation Plan (+25 k shares) and the 2019 ESPP (+50 k shares).
- A one-time option exchange was rejected (4.87 m for / 5.82 m against).
- The advisory say-on-pay resolution was also rejected (5.16 m for / 5.18 m against).
Audit: KPMG LLP was ratified for FY 2025 (13.62 m for / 2.87 m against).
The voting pattern shows notable shareholder resistance to current compensation practices—even as additional share reserves for future equity awards were endorsed—signalling potential governance scrutiny ahead.
Agenus (NASDAQ: AGEN) filed a Form 4 disclosing that director Timothy Wright received a total of 15,750 stock options on 06/17/2025 under the company’s 2019 Amended & Restated Equity Incentive Plan.
The options carry an exercise price of $3.02 and expire on 05/28/2035. Two tranches were awarded: 750 options that vest one-third on 05/28/2026 and quarterly thereafter, and 15,000 options that vest fully one year after the grant date. All awards were reported as directly held; no shares were sold or otherwise disposed. The filing is a routine disclosure of director compensation rather than a change in ownership of common stock.
Form 4 Filing Overview – Agenus Inc. (AGEN)
Director Susan B. Hirsch reported the receipt of 15,000 non-qualified stock options under the company’s 2019 Amended & Restated Equity Incentive Plan. The grant was originally approved on 28 May 2025, became effective upon shareholder approval at the 17 June 2025 annual meeting, and is therefore shown as the transaction date. Key terms are:
- Exercise price: $3.02 per share
- Vesting: 100 % on the one-year anniversary of the grant date (28 May 2026)
- Expiration: 28 May 2035 (10-year term)
- Post-transaction holdings: 15,000 derivative securities (stock options) held directly
No purchases or sales of Agenus common stock were reported, and no non-derivative holdings changed. The filing therefore represents a routine equity award intended to align director incentives rather than an open-market transaction that would signal confidence or concern about near-term fundamentals. At approximately 15 k shares, potential dilution is de-minimis relative to Agenus’ outstanding share count.
Agenus (NASDAQ: AGEN) filed a Form 4 disclosing that director Brian Corvese received two option grants totaling 30,750 derivative securities on 06/17/2025, following shareholder approval of the 05/28/2025 grant date.
The options carry a $3.02 exercise price and expire on 05/28/2035. A 750-unit grant vests one-third on 05/28/2026 with quarterly vesting thereafter, while the larger 30,000-unit grant vests fully on the one-year anniversary of the grant date. No common shares were bought or sold, so Corvese’s direct ownership only increased by the new option awards.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
